Loading news...
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026.
Standard BioTools (NASDAQ: LAB - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Profitability This table compares Standard BioTools
Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.
Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. CLOV's member retention exceeds 90%, older cohorts generate $217 monthly profit, and the Clover Assistant AI is driving clinical and financial improvements. The stock trades at less than 0.5x 2026 sales, with a fair value estimate of $3.30 per share—28% above current levels.
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Clover Health posts 53% AEP PPO membership growth, lifts total members to 153,000, and says the momentum positions it for GAAP net income profitability in 2026.
Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026. Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings and margin expansion.
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Counterpart Health , Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research demonstrating the platform's impact on chronic disease management, meaningful product expansion, and the scaled adoption of Counterpart Assistant (CA) by hundreds of live third-party customer clinicians across diverse practice settings.
Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company.
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P.
Clover Health Investments, Corp. (CLOV) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Clover Health Investments (CLOV) reported earnings 30 days ago. What's next for the stock?
Despite disappointing YTD earnings due to higher than expected medical costs, Clover's expected GAAP profitability in 2026 marks a critical inflection point. Clover's higher returning member mix and targeted growth measures aiming to bring more members under Clover Assistant quicker are major tailwinds to medical costs next year, in my opinion. Clover Assistant's early diagnosis capabilities set the company up to benefit from the CMS' Part D measures aiming to normalize cost pressures on plans, in my opinion.
WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time.
Clover Health Investments (NASDAQ: CLOV - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk. Analyst Recommendations This is a
Clover Health Investments, Corp. ( CLOV ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Kuipers - Chief Financial Officer Presentation Unknown Analyst Okay. All right.
Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.